ClinicalTrials.gg
RecruitingNCT06323915C3MUpdated Mar 21, 2024

Comparative Study of 3 Multifocal Intraocular Lenses in Murcia

An interventional study of intraocular lens implantation in cataract surgery in Cataract, sponsored by Cristalens Industrie. Recruiting at 1 site in Spain. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-03-21.

Sponsored by Cristalens Industrie · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 10 months after the study started (first participant enrolled Apr 2021, registered Mar 2024).
  • Started Apr 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Cataract with a site in Spain — 12 open to participants now, 13 under way, none of them phase 3. Cataract · Spain.

Planned enrollment
19th of 34
84 · median 100
Started
2021
with 9 others
No phase
30 of 61
7 open now
Primary completion
2025-06
later than 3 of 12 live
Registered
48th of 61
by date

Among the 61 studies in Cataract with a site in Spain, this one is the 19th largest by planned enrollment of the 34 interventional ones that give a count, is one of 10 that started in 2021, is one of 30 with no phase, reaches primary completion later than 3 of the 12 other live ones, and was the 48th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

12 of the 61 studies in Cataract with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Cataract with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the performance of 3 intraocular lenses (IOLs): FineVision (comparator), ARTIS SYMBIOSE (study lenses), and Tecnis Synergy (comparator) through binocular distance-corrected defocus curve.

This main objective will be to show superiority of the ARTIS SYMBIOSE system through binocular distance-corrected defocus curve.

The patient population to be included is patient suffering from cataract who requires cataract surgery procedure that meet the inclusion and non-inclusion criteria and provide written informed consent.

Participants will attend a total of 5 study visits: 1 preoperative visit, 1 surgery visit and 3 postoperative visits.

Read the detailed description

This trial is a single center, prospective, randomized (1:1), unblinded, controlled study conducted in Spain according to Art. 82 MDR (PMCF study).

The lead investigator at the Murcia Clínica Vista Ircovisión (Murcia Ircovision Eye Clinic) is Dr. Jerónimo LAJARA BLESA.

This study examines the visual performance of the three IOLs involved : ARTIS Symbiose (study lens) compared to FineVision (comparator), and Tecnis Synergy (comparator) in bilaterally implanted patients.

Due to the design of the ARTIS SYMBIOSE set of multifocal IOLs and the Tecnis Synergy multifocal IOL that target continuous sharp vision from far vision to near vision, this comparative trial is needed to evaluate if these approaches are able to achieve the enhancement in the patients' depth-of-field that has been reported with the FineVision trifocal IOL, which is considered as the "gold standard".

A total of approximately 84 patients will be included at 1 clinical center. Subjects participating in the study will attend a maximum of 5 study visits (1 preoperative, 1 operative and 3 postoperative visits) over a period of 12 months.

Only patients who have age-related cataracts will be included in the study. To participate in this study, patients must be at least 50 years old at the time of screening and maximum 85 years old. All patients who would like to take part in this study will receive a detailed study information by the investigator staff and a written informed form. Before a patient is admitted, he or she must sign a consent form.

The primary study endpoint is to compare the performance of 3 IOLs (FineVision, ARTIS SYMBIOSE, and Tecnis Synergy) through binocular distance-corrected defocus curve.

The entire study including data processing will be carried out in accordance with EN ISO 14155:2020 Clinical Investigation of Medical Devices for Human Subjects, EN ISO 11979-7:2018: Clinical investigations of intraocular lenses for the correction of aphakia, EU MDR 2017/745, MEDDEV 2.7.1 rev. 4 Clinical Evaluation: A Guide for Manufacturers and Notified Bodies, MPDG:2020: Medical Device Law Implementation Act, as well as applicable local regulations and the Declaration of Helsinki.

03

Conditions studied

  • Cataract

Browse trials for

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 50 \< Age \< 85 years old
  • Bilateral age-related cataract
  • Signed of the study
  • Availability, willingness and sufficient cognitive awareness to comply with examination procedures
  • Qualify for bilateral implantation within 1 month
  • No previous refractive or ocular surgery
  • Need for IOL in this diopter range: 10 to 30 D
  • Expected postoperative astigmatism ≤ 0.75 D
  • Eye dryness ≤ 2 in dry eye severity grading

Non-inclusion criteria:

  • Being under guardianship / curatorship
  • Illiterate or not enough knowledge of Spanish language
  • Acute or chronic disease or illness that would increase risk or confound study results found to be relevant by the investigators
  • Pupil > 4mm or \< 2mm in photopic conditions
  • Occupation requiring night-time driving or any occupation incompatible with multifocality
  • Amblyopia, strabismus, color blindness
  • Extremely shallow anterior chamber
  • Capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome, uveitis, Marfan's syndrome).
  • Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils or pupils that do not dilate under mesopic/scotopic conditions).
  • Irregular astigmatism, unstable cornea.

Exclusion criteria

Exclusion Criteria:

  • Inability to place the intraocular lens safely at the location planned
  • Surgical complications (e.g. non-circular rhexis, oversized or undersized rhexis). Each patient with these intraoperative complications should not be implanted with the study IOL
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Active comparator
    FineVision

    28 patients will be implanted bilaterally with Intensity FineVision (PhysIOL, Belgium) trifocal IOLs. The device is CE-marked and used according to the intended purpose.

    Device: intraocular lens implantation in cataract surgery

  • Active comparator
    Artis Symbiose

    28 patients will be implanted bilaterally with Artis Symbiose (Cristalens Industrie, France) IOLs. The device is CE-marked and used according to the intended purpose.

    Device: intraocular lens implantation in cataract surgery

  • Active comparator
    Synergy

    28 patients will be implanted bilaterally with Tecnis Synergy model ZFR00V (Johnson \& Johnson, USA) IOLs. The device is CE-marked and used according to the intended purpose.

    Device: intraocular lens implantation in cataract surgery

Interventions

  • Deviceintraocular lens implantation in cataract surgery

    Implantation of intra ocular lenses in both patient's eyes in remplacement of the natural cataracted cristallin that has been removed from the patient's eye during the cataract surgery

06

What researchers measure

Primary outcomes

  1. defocus curve comparison

    The defocus curves will be carried out from + 1.00 D to - 4.00D with measures of binocular visual acuity in LogMAR with ETDRS (Early Treatment Diabetic Retinopathy Study) chart at 1 month. The primary endpoint is visual acuity assessed by depth of field at 0 logMAR.

    Time frame: one month

07

Study locations

1 of 1 sites recruiting
  • Vista Clinic Ircovision Murcia
    Murcia, 30008, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Jun 2025, 50 months after the start.

Of 190 industry-sponsored interventional studies with no phase under Cataract, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's planned 50 months is above that.

Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2024
First posted
Mar 21, 2024
StartActual
Apr 20, 2021
Primary completionEst.
Jun 20, 2025
CompletionEst.
Sep 20, 2025
Last update
Mar 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06323915
Lead sponsor
Cristalens Industrie
Responsible party
Sponsor
First posted
Mar 21, 2024
Start date
Apr 20, 2021
Primary completion
Jun 20, 2025 (estimated)
Completion
Sep 20, 2025 (estimated)
Last update
Mar 21, 2024

Study contacts

Sylvie Lebeau
Contact
s.lebeau.ci@cristalens.fr
+33 (0)2 96 48 92 92

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion